Definium'un LSD Hapı İkinci Bir Kaygı Denemesini Temizledi ve Psychedelics Sektörü İzliyor

Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching

Sheryar Siddiq

Sun, September 20, 2026 at 7:28 PM GMT+3 3 min read

DFTX +0.34%

Definium Therapeutics, Inc. (NASDAQ:DFTX) has now delivered a third consecutive positive Phase 3 readout for its LSD-based medication, the second in generalized anxiety disorder. The result puts the company on a viable route toward a potential FDA approval of an LSD-based treatment for generalized anxiety disorder, and considering how closely psychedelic stocks have historically traded on each other's data, the reading carries far more weight than Definium's own ticker.

A Third Positive Phase 3 Readout in Under a Year

On September 14, Definium Therapeutics, Inc. (NASDAQ:DFTX) announced that its drug DT120, an orally disintegrating tablet formulation of LSD, was successful in Panorama, the company's second late-stage anxiety trial. Over 12 weeks, patients who received a 100-microgram dose experienced a 9.8-point decline on the Hamilton Anxiety Rating Scale, a typical clinical measure, compared to a 4.7-point drop with placebo.

The resulting 5.1-point placebo-adjusted improvement is similar to what the company's first pivotal anxiety trial, Voyage, showed back in August: an 11.6-point improvement versus 6.2 for placebo, a 5.4-point separation that Jefferies called one of the strongest placebo-adjusted efficacy results ever seen in generalized anxiety disorder, and that Stifel simply described as "a clean win."

A Sector Trading as a Group

Psychedelic equities have a history of trading as a group rather than as individual names, and this tendency applies both ways. In February 2026, when Compass Pathways, the sector's other clinical leader developing a psilocybin-based drug for treatment-resistant depression, reported positive late-stage data, shares of Definium Therapeutics, Inc. (NASDAQ:DFTX), Atai Beckley, GH Research, and Helus Pharma all rose, some by double digits.

That correlation is significant here because Definium's win is an independent validation of the broader therapeutic argument on which Compass and others are betting: a single dose of a classic psychedelic, administered in a controlled clinical setting, can produce lasting improvements in serious mental health conditions via pathways different from existing SSRIs and other standard-of-care drugs.

Hedge Fund Positioning

Hedge fund holdings of Definium Therapeutics, Inc. (NASDAQ:DFTX) increased substantially, up from 46 funds in the first quarter to 72 in the second, indicating a significant buildup of institutional confidence ahead of this second consecutive positive GAD readout.

What This Means Going Forward

For Definium Therapeutics, Inc. (NASDAQ:DFTX), three straight favorable Phase 3 findings across two indications greatly decrease the risk of a first approval, and the company's upcoming pre-NDA meeting is the next tangible step toward a submission. For the sector as a whole, this result is less important for what it says about Definium's stock and more for what it implies about the underlying science: a second pivotal confirmation of efficacy in the same indication, using the same drug, reduces the possibility that Voyage's result was a statistical fluke, and could provide a sentiment tailwind for other psychedelic developers, although each program still has to establish its own efficacy, safety, and regulatory case.

The Verdict

Investors in the space should pay close attention to two things: whether sector peers' shares move in response to this news, as has been the case in the past, and whether Definium's NDA submission is completed on time in the first half of 2027, as a smooth regulatory path from here would be the clearest signal that this class of drug is progressing from clinical promise to commercial reality.

While we acknowledge the potential of DFTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

Disclosure: None. Follow Insider Monkey on Google News.